Replies to post #7984 on Cellectar Biosciences Inc (CLRB)

[Sluicebox]

It's a real shame about the watering out of shareholders during the last many year, happy I was not part of that. And the mgm might not be the best.

But it doesn't change the fact that CLR-131 is a very interesting candidate with some very exiting trial results.
Just revisited their lates clinical presentation and think it is good news all around.
Just the fact that the MOA of CLR-131 is unique makes it relevant in later lines.


I look forward to the Clover-1 trial that will hopefully readout beginning of Q3. Strongly believe that the 2-cycle dosing will show solid results.

Also looking forward to update on phase I Pediatric Brain & Solid Tumors.